STOCK TITAN
  1. Home
  2. News
  3. TNGX

Tango Therapeutics Inc - TNGX STOCK NEWS

Welcome to our dedicated news page for Tango Therapeutics (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tango Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tango Therapeutics's position in the market.

News
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Tango Therapeutics (TNGX) grants stock options and restricted stock units to a new employee under its 2023 Inducement Plan. The options have an exercise price of $7.64 per share and will vest over time, while the RSUs will vest in three annual installments. This move aims to attract and retain talent crucial for developing precision cancer medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
News
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
Rhea-AI Summary
Tango Therapeutics, Inc. (TNGX) reports strong financial results for Q4 2023, with a cash position of $337 million and ongoing dose escalation in four precision oncology programs. FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas. Business highlights include first patient dosed in TNG348 trial. The company remains well-funded into late 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
earnings
-
News
Tango Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced CEO Barbara Weber's participation in upcoming investor conferences in March. The company focuses on precision cancer medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
conferences
News
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Tango Therapeutics, Inc. announces multiple abstracts accepted for presentation at AACR Annual Meeting 2024, showcasing innovative cancer therapies and potential new treatments. The company's focus on precision cancer medicines is evident in the diverse range of topics covered in the abstracts, highlighting their commitment to advancing cancer research and treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
clinical trial
-
News
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced that Barbara Weber, M.D., President and CEO, will present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on February 7, 2024. A live webcast of the presentation will be available on the Company's website, with a replay archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
News
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) granted a non-qualified stock option to purchase 172,500 shares of its common stock and 26,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The options have an exercise price of $9.98 per share, equal to the closing price of Tango Therapeutics' common stock on January 2, 2024. The RSU award will vest in three equal annual installments, subject to the employee's continued employment. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, approved in February 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
Rhea-AI Summary
Medivir AB (MVIR) Announces First Patient Dosed with TNG348, a Novel USP1 Inhibitor by Licensee Tango Therapeutics (TNGX) for the Treatment of HRD+ Cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
clinical trial
-
News
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the dosing of the first patient in the phase 1/2 trial evaluating TNG348, a novel selective inhibitor of USP1, as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ cancers. The U.S. FDA granted TNG348 Fast Track designation in September 2023. The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG348 in patients with HRD+ cancers, which represent a significant portion of ovarian, breast, prostate, and pancreatic cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
clinical trial
-
News
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the selection of two abstracts for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting. The abstracts support the clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers, including glioblastoma and malignant peripheral nerve sheath tumors. The data demonstrate the potential of these inhibitors as new therapies for patients with MTAP-deleted cancers, with strong antitumor activity and well-tolerated doses. The phase 1/2 trials for TNG908 and TNG462 are ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
clinical trial
News
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Rhea-AI Summary
Tango Therapeutics, Inc. (NASDAQ: TNGX) reported progress in trials of lead PRMT5 inhibitors and CoREST inhibitor TNG260, FDA Fast Track designation for USP1 inhibitor TNG348, and a strong cash position of $360 million expected to fund clinical programs through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
earnings
Stock TNGX logo
Tango Therapeutics Inc

Nasdaq:TNGX

TNGX Rankings

#2602 Ranked by Market Cap
#2017 Ranked by Stock Gains
N/A Ranked by Dividends

TNGX Stock Data

785.44M
46.25M
13.51%
88.51%
9.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About TNGX

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util